Kiniksa Pharmaceuticals, Ltd. — Q2 2019 Form 10-Q
Reporting period: Three and six months ended June 30, 2019. The filing identifies the registrant as Kiniksa Pharmaceuticals, Ltd. The company is a clinical-stage biopharmaceutical business focused on autoimmune and autoinflammatory diseases; it has no approved products and has generated no product revenue.
Financial performance and position
| Metric | Q2 2019 / June 30, 2019 | Comparable period / prior year-end |
|---|---|---|
| Product revenue | None | None |
| Operating expenses | $39.3 million for Q2; $106.9 million for the first half | $21.5 million for Q2 2018; $37.9 million for first-half 2018 |
| Research and development | $30.8 million for Q2; $90.1 million for the first half | $17.2 million for Q2 2018; $29.8 million for first-half 2018 |
| General and administrative | $8.4 million for Q2; $16.8 million for the first half | $4.3 million for Q2 2018; $8.0 million for first-half 2018 |
| Net loss | $37.2 million for Q2; $103.0 million for the first half | $20.3 million for Q2 2018; $36.2 million for first-half 2018 |
| Loss per share, basic and diluted | $0.68 for Q2; $1.94 for the first half | $1.11 for Q2 2018; $3.45 for first-half 2018 |
| Cash, cash equivalents and short-term investments | $287.4 million | $307.3 million at December 31, 2018 |
| Operating cash flow | $(104.9) million for the first half | $(32.9) million for first-half 2018 |
| Total assets / liabilities | $308.1 million / $32.9 million | $322.0 million / $42.7 million at December 31, 2018 |
There is no meaningful revenue margin because the company has no product sales; operating expenses therefore drove operating losses. Interest income was $1.7 million for Q2 and $3.5 million for the first half. The filing does not report conventional borrowing or funded debt; reported liabilities include operating leases and other operating obligations. Current assets were $296.5 million against current liabilities of $30.2 million.
Material changes versus prior periods
- Q2 operating expenses rose $17.8 million year over year, and net loss increased $16.9 million. First-half operating expenses rose $69.1 million and net loss increased $66.8 million.
- First-half R&D expense included $18.0 million for the Primatope acquisition and $10.0 million for a Biogen clinical milestone. R&D also increased as clinical programs advanced and staffing, manufacturing, and trial costs grew.
- G&A rose with hiring and public-company, legal, accounting, and other professional costs.
- First-half financing provided $83.7 million, primarily from a February 2019 follow-on offering and concurrent private placement. The company reported $83.0 million of net proceeds from these transactions. Cash and cash equivalents increased by $10.8 million during the first half, while short-term investments declined.
Outlook, risks, and unusual items
- Management expects existing cash, cash equivalents, and short-term investments to fund operating and capital needs for at least 12 months from issuance of the financial statements. The company expects continued losses and rising R&D spending; funding beyond that period depends on raising additional capital. No quantified earnings or revenue guidance is provided.
- Clinical milestones expected at the time of the filing included rilonacept Phase 3 RHAPSODY top-line results in the second half of 2020; mavrilimumab Phase 2 GCA top-line data in the second half of 2020; and KPL-716 prurigo nodularis Phase 2a top-line data in the first half of 2020. The company expected KPL-404 to file an IND in the second half of 2019 and begin Phase 1 in the first half of 2020. These are forward-looking expectations, not assured outcomes.
- Key risks include clinical-trial failure or delay, regulatory and safety uncertainty, manufacturing and single-source supplier dependence, competition, intellectual-property exposure, and the need for future financing, which could dilute shareholders or constrain programs.
- Primatope was acquired in March 2019 and treated as an asset acquisition; related in-process R&D was expensed. The company also adopted the new lease accounting standard on January 1, 2019, recognizing lease right-of-use assets and liabilities. No material litigation was reported.
- Management concluded disclosure controls were effective as of June 30, 2019 and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether clinical enrollment, data readouts, and regulatory milestones remain on schedule, and whether subsequent results support the stated development plans.
- How the cash runway changes as operating cash use accelerates; the stated 12-month runway depends on management assumptions and does not assure financing thereafter.
- The components and timing of R&D spending, particularly milestone and acquisition-related expenses, versus recurring clinical-development costs.
- Potential dilution and voting control: the company had 54,857,692 common shares outstanding as of July 31, 2019, with a multi-class structure and significant voting influence among certain holders.
- Potential future milestone, royalty, and manufacturing commitments under licensing and acquisition agreements; the filing reports minimum manufacturing commitments of $7.0 million at June 30, 2019.